Teresa Macarulla

Also affiliated with Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 9 papers. Top paper: “NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial”.

NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial

The Lancet(2023)10.1016/s0140-6736(23)01366-1

N/A

5.4DataRank · unranked

454 citations

Davide Melisi, Teresa Macarulla, Roberto Pazo-Cid, Sreenivasa R Chandana, Christelle de la Fouchardière +14 more

Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Journal of Clinical Oncology(2022)10.1200/jco.21.01604

N/A

4.0DataRank · unranked

230 citations

Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J. Hall +14 more

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

British Journal of Cancer(2020)10.1038/s41416-020-01041-x

N/A

2.6DataRank · unranked

90 citations

Michael S. Gordon, Monica Mita, Brian I. Rini, Vicky Makker, Teresa Macarulla +15 more

First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study

European Journal of Cancer(2021)10.1016/j.ejca.2021.03.028

N/A

0.604DataRank · unranked

55 citations

Tanios Bekaii‐Saab, Patrick M. Boland, Farshid Dayyani, Teresa Macarulla, Kabir Mody +8 more

SRC inhibition enables formation of a growth suppressive MAGI1-PP2A complex in isocitrate dehydrogenase-mutant cholangiocarcinoma

Science Translational Medicine(2024)10.1126/scitranslmed.adj7685

N/A

0.425DataRank · unranked

16 citations

Caroline M. Bridgwater, Angela Yu, Liberalis Debraj Boila, Mariana Yáñez-Bartolomé, Aaron Lampano +17 more

Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study

The Lancet Regional Health - Europe(2024)10.1016/j.lanepe.2024.101063

N/A

0.292DataRank · unranked

6 citations

Berta Martin-Cullell, Vı́ctor Navarro, Kreina Sharela Vega, Jordi Recuero-Borau, Diego Gómez-Puerto +37 more

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

Cancer Research(2022)10.1158/0008-5472.can-21-2409

N/A

0DataRank · unranked

98 citations

Andrea Herencia-Ropero, Alba Llop‐Guevara, Flaminia Pedretti, Alejandro Moles‐Fernández, Cristina Viaplana +34 more

Data from Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

(2023)10.1158/0008-5472.c.6513876.v1

N/A

0DataRank · unranked

0 citations

Andrea Herencia-Ropero, Alba Llop‐Guevara, Flaminia Pedretti, Alejandro Moles‐Fernández, Cristina Viaplana +34 more

MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor–Resistant Cholangiocarcinoma and Attenuate the IFN Response

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-3284

N/A

0DataRank · unranked

3 citations

Hatice D. Saatcioglu, Haley Ellis, Elia Aguado-Fraile, Qin Xu, Hiroshi Kondo +20 more